Official Patient site for YORVIPATH for chronic hypoparathyroidism in adults. See full Prescribing Information & Important Safety Information.

May 21, 2025 · ORLANDO, Fla. — After 2 years of treatment with the parathyroid hormone (PTH) analog palopegteriparatide (Yorvipath), adults with chronic hypoparathyroidism demonstrated …

Sep 15, 2023 · What benefits of Yorvipath have been shown in studies? One main study involving 84 patients with hypoparathyroidism showed that Yorvipath was effective at keeping blood calcium …

Is Yorvipath Right for Me? Your health care provider may consider treatment with Yorvipath if you have hypoparathyroidism and have been taking calcium and vitamin D treatment.

Patients who may benefit can include patients with: *Hyperphosphatemia *corrected calcium below target levels or symptomatic hypocalcemia *Hypercalcuria or nephrolithiasis despite thiazide use …

May 18, 2025 · ORLANDO -- Palopegteriparatide (Yorvipath) led to sustained improvements over 2 years in adults with chronic hypoparathyroidism, according to long-term phase III PaTHway trial results.

Other Yorvipath (palopegteriparatide) is considered not medically necessary for members who do not meet the criteria set forth above. Members currently receiving the requested medication as samples …

POLICY STATEMENT Prior Authorization is recommended for prescription benefit coverage of Yorvipath. All approvals are provided for the duration noted below. Because of the specialized skills …

Aug 12, 2024 · At launch, Ascendis plans to offer a suite of patient services for YORVIPATH through its U.S. Ascendis Signature Access Program (A.S.A.P.), including support navigating the treatment …

The Ascendis Patient Assistance Program is intended to provide assistance for patients using the medication for its’ approved indications. e and insurance eligibility will be reconfirmed periodically. If …